Skip to main content

Advertisement

SpringerLink
Log in

Visual field after anti-vascular endothelial growth factor therapy and laser treatment for retinopathy of prematurity

  • Pediatrics
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the visual field after anti-vascular endothelial growth factor (VEGF) therapy and laser treatment for retinopathy of prematurity.

Method

Retrospective cohort study. Infants with retinopathy of prematurity treated by anti-VEGF therapy or laser treatment were included in the study. Degrees of visual field in eight directions examined by Goldmann perimeter (intensity, 1000 apostilb; size, V4e = 64 mm2) were compared between the anti-VEGF therapy and laser treatment groups. The visual acuity (VA) and spherical equivalent refraction were also compared between the two groups.

Results

Nine eyes with anti-VEGF therapy and 12 eyes with laser treatment were enrolled in the analysis. The total, upper, nasal upper, nasal, nasal lower, temporal lower, and temporal upper visual fields were significantly wider in the eyes with anti-VEGF therapy than in those with laser treatment (496 vs 416, P = .002; 53 vs 45, P = .008; 56 vs 43, P = .003; 58 vs 39, P < .001; 55 vs 44, P = .01; 72 vs 65, P = .01; and 62 vs 56, P = .03, respectively). The logarithm of the minimum angle of resolution VA tended to be better in the eyes with anti-VEGF therapy than in those with laser treatment (0.01 vs 0.15, P = .06). Eyes with anti-VEGF therapy had significantly lower myopia than those with laser treatment (spherical equivalent refraction: -0.72 vs -5.7, P = .001).

Conclusion

Anti-VEGF therapy may provide a wider visual field, better VA, and less myopia compared with laser treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Gilbert C (2008) Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev 84:77–82. https://doi.org/10.1016/j.earlhumdev.2007.11.009

    Article  PubMed  Google Scholar 

  2. Quinn GE, Dobson V, Davitt BV, Hardy RJ, Tung B, Pedroza C, Good WV, Early Treatment for Retinopathy of Prematurity Cooperative G (2008) Progression of myopia and high myopia in the early treatment for retinopathy of prematurity study: findings to 3 years of age. Ophthalmology 115:1058-1064 e1051. https://doi.org/10.1016/j.ophtha.2007.07.028

    Article  PubMed  Google Scholar 

  3. Quinn GE, Dobson V, Davitt BV, Wallace DK, Hardy RJ, Tung B, Lai D, Good WV, Early Treatment for Retinopathy of Prematurity Cooperative G (2013) Progression of myopia and high myopia in the early treatment for retinopathy of prematurity study: findings at 4 to 6 years of age. J AAPOS 17:124–128. https://doi.org/10.1016/j.jaapos.2012.10.025

    Article  PubMed  PubMed Central  Google Scholar 

  4. McLoone E, O’Keefe M, McLoone S, Lanigan B (2007) Effect of diode laser retinal ablative therapy for threshold retinopathy of prematurity on the visual field: results of Goldmann perimetry at a mean age of 11 years. J Pediatr Ophthalmol Strabismus 44:170–173. https://doi.org/10.3928/0191-3913-20070301-10

    Article  PubMed  Google Scholar 

  5. Early Treatment For Retinopathy Of Prematurity Cooperative G (2003) Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 121:1684–1694. https://doi.org/10.1001/archopht.121.12.1684

    Article  Google Scholar 

  6. Mintz-Hittner HA, Kennedy KA, Chuang AZ, Group B-RC (2011) Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 364:603–615. https://doi.org/10.1056/NEJMoa1007374

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Geloneck MM, Chuang AZ, Clark WL, Hunt MG, Norman AA, Packwood EA, Tawansy KA, Mintz-Hittner HA, Group B-RC (2014) Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol 132(1327):1333. https://doi.org/10.1001/jamaophthalmol.2014.2772

    Article  Google Scholar 

  8. Pertl L, Steinwender G, Mayer C, Hausberger S, Poschl EM, Wackernagel W, Wedrich A, El-Shabrawi Y, Haas A (2015) A systematic review and meta-analysis on the safety of vascular endothelial growth factor (VEGF) inhibitors for the treatment of retinopathy of prematurity. PLoS One 10:e0129383. https://doi.org/10.1371/journal.pone.0129383

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Tahija SG, Hersetyati R, Lam GC, Kusaka S, McMenamin PG (2014) Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity. Br J Ophthalmol 98:507–512. https://doi.org/10.1136/bjophthalmol-2013-304109

    Article  PubMed  Google Scholar 

  10. Roohipoor R, Karkhaneh R, Riazi-Esfahani M, Dastjani Farahani A, Khodabandeh A, Ebrahimi Adib N, Imani M, Khojasteh Jafari H, Riazi-Esfahani H, Hosseinpour J, Zarei M, Ghasemi H, Mirghorbani M, Yaseri M, Davoudi S, Modjtahedi BS (2018) Comparison of intravitreal bevacizumab and laser photocoagulation in the treatment of retinopathy of prematurity. Ophthalmol Retin 2:942–948. https://doi.org/10.1016/j.oret.2018.01.017

    Article  Google Scholar 

  11. Perente I, Eris E, Seymen Z, Cevik SG, Bekmez S (2019) Aggressive posterior retinopathy of prematurity treated with intravitreal bevacizumab: late period fluorescein angiographic findings. Graefes Arch Clin Exp Ophthalmol 257:1141–1146. https://doi.org/10.1007/s00417-019-04292-4

    Article  CAS  PubMed  Google Scholar 

  12. Lepore D, Quinn GE, Molle F, Orazi L, Baldascino A, Ji MH, Sammartino M, Sbaraglia F, Ricci D, Mercuri E (2018) Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings. Ophthalmology 125:218–226. https://doi.org/10.1016/j.ophtha.2017.08.005

    Article  PubMed  Google Scholar 

  13. Lorenz B, Stieger K, Jager M, Mais C, Stieger S, Andrassi-Darida M (2017) Retinal vascular development with 0.312 mg intravitreal bevacizumab to treat severe posterior retinopathy of prematurity: a longitudinal fluorescein angiographic study. Retina 37:97–111. https://doi.org/10.1097/IAE.0000000000001126

    Article  CAS  PubMed  Google Scholar 

  14. International Committee for the Classification of Retinopathy of P (2005) The international classification of retinopathy of prematurity revisited. Arch Ophthalmol 123:991–999. https://doi.org/10.1001/archopht.123.7.991

    Article  Google Scholar 

  15. Hajrasouliha AR, Garcia-Gonzales JM, Shapiro MJ, Yoon H, Blair MP (2017) Reactivation of retinopathy of prematurity three years after treatment with bevacizumab. Ophthalmic Surg Lasers Imaging Retina 48:255–259. https://doi.org/10.3928/23258160-20170301-10

    Article  PubMed  Google Scholar 

  16. Snyder LL, Garcia-Gonzalez JM, Shapiro MJ, Blair MP (2016) Very late reactivation of retinopathy of prematurity after monotherapy with intravitreal bevacizumab. Ophthalmic Surg Lasers Imaging Retina 47:280–283. https://doi.org/10.3928/23258160-20160229-12

    Article  PubMed  Google Scholar 

  17. Ittiara S, Blair MP, Shapiro MJ, Lichtenstein SJ (2013) Exudative retinopathy and detachment: a late reactivation of retinopathy of prematurity after intravitreal bevacizumab. J AAPOS 17:323–325. https://doi.org/10.1016/j.jaapos.2013.01.004

    Article  PubMed  Google Scholar 

  18. Gundlach BS, Kokhanov A, Altendahl M, Suh SY, Fung S, Demer J, Pineles S, Khitri M, Chu A, Tsui I (2022) Real-world visual outcomes of laser and anti-VEGF treatments for retinopathy of prematurity. Am J Ophthalmol 238:86–96. https://doi.org/10.1016/j.ajo.2021.11.015

    Article  CAS  PubMed  Google Scholar 

  19. Lee YS, See LC, Chang SH, Wang NK, Hwang YS, Lai CC, Chen KJ, Wu WC (2018) Macular structures, optical components, and visual acuity in preschool children after intravitreal bevacizumab or laser treatment. Am J Ophthalmol 192:20–30. https://doi.org/10.1016/j.ajo.2018.05.002

    Article  PubMed  Google Scholar 

  20. Chen YC, Chen SN (2020) Foveal microvasculature, refractive errors, optical biometry and their correlations in school-aged children with retinopathy of prematurity after intravitreal antivascular endothelial growth factors or laser photocoagulation. Br J Ophthalmol 104:691–696. https://doi.org/10.1136/bjophthalmol-2019-314610

    Article  PubMed  Google Scholar 

  21. Zhao J, Wu Z, Lam W, Yang M, Chen L, Zheng L, Zhang F, Zeng J, Wang J, Zhang G (2020) Comparison of OCT angiography in children with a history of intravitreal injection of ranibizumab versus laser photocoagulation for retinopathy of prematurity. Br J Ophthalmol 104:1556–1560. https://doi.org/10.1136/bjophthalmol-2019-315520

    Article  PubMed  Google Scholar 

  22. Inoue T, Asaoka R, Hashimoto Y, Kitamoto K, Kitano M, Fujita A, Azuma K, Yamamoto K, Nagahara M, Kadonosono K, Obata R (2021) Does the number of laser applications for ROP treatment influence the degree of myopia? Graefes Arch Clin Exp Ophthalmol 259:317–322. https://doi.org/10.1007/s00417-020-04946-8

    Article  PubMed  Google Scholar 

  23. Matsumura S, Matsumoto T, Katayama Y, Tomita M, Morikawa H, Itokawa T, Kawakami M, Hori Y (2022) Risk factors for early-onset high myopia after treatment for retinopathy of prematurity. Jpn J Ophthalmol 66:386–393. https://doi.org/10.1007/s10384-022-00921-4

    Article  PubMed  Google Scholar 

  24. Quinn GE, Fea AM, Minguini N (1991) Visual fields in 4- to 10-year-old children using Goldmann and double-arc perimeters. J Pediatr Ophthalmol Strabismus 28:314–319. https://doi.org/10.3928/0191-3913-19911101-07

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Robert Blakytny, D. Phil., from Edanz (https://jp.edanz.com/ac) for editing a draft of this manuscript.

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Shiga University of Medical Science, Otsu, Japan

    Shumpei Obata, Riko Matsumoto, Maki Iwasa, Masashi Kakinoki, Osamu Sawada, Tomoko Sawada, Yoshitsugu Saishin & Masahito Ohji

Authors
  1. Shumpei Obata
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Riko Matsumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maki Iwasa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masashi Kakinoki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Osamu Sawada
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tomoko Sawada
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yoshitsugu Saishin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Masahito Ohji
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shumpei Obata.

Ethics declarations

Ethics approval

All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The study was approved by the Institutional Review Board/Ethics Committee of Shiga University of Medical Science (Otsu, Japan).

Consent to participate

For this study, an opt-out consent process was used at Shiga University of Medical Science Hospital after approval by the Institutional Review Board.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Obata, S., Matsumoto, R., Iwasa, M. et al. Visual field after anti-vascular endothelial growth factor therapy and laser treatment for retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 261, 3207–3213 (2023). https://doi.org/10.1007/s00417-023-06227-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-023-06227-6

Keywords

Search

Navigation